The third issue of the ASSET Paper Series focuses on some highly delicate topics that lie at the intersection of science, ethics, politics, and economics. In the first article of the collection, Donato Greco, epidemiologist and public health expert, discusses about the role and the management of national borders when dealing with both the spread of an infectious disease and the flow of migrants or refugees, citing the recent EU decision on such a matter.
In the context of a Europe increasingly hesitant about vaccination, with dropping vaccination coverage,Immuniser Lyon was a French campaign aiming to re-inform the population of the greater Lyon area in centre-east of France, of the proven benefits of vaccination and to incite people of all ages (children, adults, seniors) to be up-to-date with their vaccinations.
The fact that some vaccine preventable diseases have disappeared or are very rare following these vaccination programs can lead to parents believing there is no more need to vaccinate. Therefore, it is of huge importance that events like the European Immunization, helping maintain vaccination awareness and giving accurate and understandable information on immunization, exist. In this way, public confidence in immunization is less susceptible to be influenced by groups, websites or campaigns against vaccination. By acknowledging that every child deserves a healthy start in life, countries can use the European Immunization Week to increase awareness of the importance of immunization and to strengthen their immunization systems.
Ilaria Capua, as director of the One Health Excellence Centre at the Emerging Pathogens Institute of the University of Florida, USA, is very busy in coordinating interdisciplinary research, facing the epidemic of zika virus disease spreading in South America and the Caribbean and reaching Florida. Scientists are testing new diagnostic tests and working on vaccines, but the risk of serious birth defects in the offspring of infected pregnant women calls also for responsible procreative choices, involving lawmakers, governments and religious leaders as well.
Since the thalidomide tragedy in the late1950s, there has been a reluctance to include women of childbearing age in clinical trials. However, this fear cannot be used as an excuse to not include females in clinical trials, and, with proper care and regulation, increased female participation has been reached. The United States adopted regulation early on to increase the participation of women, while a new regulation in Europe is going to improve this as well. Here follows an overview of the issue in Canada and in the USA. The third part of this series will deal with new regulation in Europe.
